查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1733155

全球血浆市场规模（按成分、最终用户、区域范围和预测）

Global Blood Plasma Market Size By Component (Immunoglobulin, Albumin), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

等离子市场规模及预测

2024 年等离子市场规模价值为 412.6 亿美元，预计到 2032 年将达到 834.4 亿美元，2026 年至 2032 年的复合年增长率为 9.2%。

  • 血浆是血球（红血球、白血球和血小板）被移除后剩下的淡黄色液体。血浆约占总血液量的 55%，主要由水（约 90%）、蛋白质、电解质、荷尔蒙、营养物质和废物组成。
  • 血浆是将这些物质运送到全身的重要载体，在维持血压、酸碱平衡和整体体内平衡方面发挥着至关重要的作用。
  • 血浆具有多种医疗用途，特别是在输血医学和治疗方面。血浆对于血友病患者生产凝血因子浓缩物至关重要，也用于製备免疫球蛋白以治疗各种免疫力缺乏。
  • 此外，白蛋白和凝血因子等血浆衍生产品对于治疗肝病、休克和烧烫伤等病症至关重要。近年来，等离子体也因其在再生医学中的潜力而受到关注，包括创伤治疗和美容治疗中的应用。

全球血浆市场动态

影响全球等离子市场的关键市场动态是：

关键市场驱动因素

  • 对血浆衍生疗法的需求不断增长：对血浆衍生疗法的需求不断增长是血浆市场的主要驱动力。血友病和免疫力缺乏等疾病需要这些治疗才能有效。根据血浆蛋白治疗协会 (PPTA) 的数据，全球血浆衍生疗法市场预计将在 2023 年达到 286 亿美元，到 2028 年的复合年增长率为 6.8%。
  • 提高捐血意识：提高捐血重要性的认知导致血浆供应增加。公共卫生宣传活动鼓励更多人捐血，从而扩大血浆供应。根据血浆蛋白治疗协会 (PPTA) 的数据，全球血浆衍生疗法市场预计将在 2023 年达到 286 亿美元，到 2028 年的复合年增长率为 6.8%。
  • 慢性病发病率不断上升：自体免疫疾病等慢性病的增加推动了对血浆产品的需求。这一趋势凸显了血浆在管理复杂健康状况中的重要作用。根据美国疾病管制与预防中心 (CDC) 的数据，截至 2023 年，美国美国患有自体免疫疾病的比例预计将从 2018 年的 4.5% 上升至 6%。
  • 增加对生物技术的投资：增加对生物技术和研究的投资正在加强血浆衍生产品的开发。加工和配方方面的创新正在带来更有效的治疗方法和更广泛的用途。根据美国国立卫生研究院（NIH）的报告，2023财年与血浆衍生疗法相关的研究支出将达到12亿美元，比上年度增加15%。
  • 增加对血浆产品的监管支持：增加对血浆产品安全性和有效性的监管支持正在建立市场信心。这种支持性环境鼓励製造商投资于品质改进和新产品开发。 FDA 报告称，2023 年核准的血浆衍生疗法数量将比 2020 年增加 30%，反映出核准流程更加简化，人们对这些产品的信心也增强。

主要问题

  • 法规日益增多：有关血浆收集和使用的法规日益增多可能会阻碍市场扩张。遵守严格的指导方针会增加製造商和经销商的复杂性和成本。
  • 对捐赠者安全的日益担忧：对捐赠者安全和潜在副作用的日益担忧可能会影响血浆供应。这些担忧可能会阻止人们捐血并导致供不应求。
  • 社会认知问题日益严重：与捐血和血浆产品相关的社会认知问题日益严重可能成为市场成长的障碍。错误讯息和负面情绪可能会阻碍潜在的捐血和消费者。
  • 来自替代疗法的竞争日益激烈：来自替代疗法和治疗方法的竞争日益激烈，对血浆市场构成了挑战。新兴技术可能提供替代疗法并减少对传统血浆疗法的依赖。

主要趋势

  • 更重视免疫球蛋白疗法：更重视免疫球蛋白疗法正在改变血浆市场。随着人们越来越认识到免疫球蛋白治疗免疫力缺乏和自体免疫疾病的有效性，其需求也正在飙升。医疗保健提供者越来越多地采用免疫球蛋白疗法，从而增加了对血浆收集和处理的投资。这一趋势凸显了血浆衍生产品在现代医学中的重要角色。
  • 对血浆衍生生技药品的需求不断增加：对凝血因子和白蛋白等血浆衍生生技药品的需求不断增加，它们对于治疗各种疾病至关重要。这一趋势是由对慢性疾病、外科手术和创伤护理日益增长的需求所推动的。随着越来越多的患者需要这些救命的疗法，製造商正在扩大其产品线以满足这一需求。对高品质生技药品的重视正在推动血浆处理技术的创新。
  • 自动血浆采集的采用率不断提高：自动血浆采集技术的采用率不断提高，并且正在彻底改变整个产业。自动化提高了血浆采集过程的效率和安全性，从而提高了产量并改善了捐赠者的体验。这些先进系统的实施将使设施能够满足日益增长的等离子产品需求。这种趋势不仅简化了业务，而且还透过最大限度地减少采集过程中的不适来帮助吸引更多的捐赠者。

目录

第一章 全球等离子市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球等离子市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球血浆市场：依成分

  • 概述
  • 免疫球蛋白
  • 白蛋白
  • 凝血因子浓缩物
  • 其他的

6. 全球等离子市场（依最终用户）

  • 概述
  • 医院
  • 诊所
  • 实验室

7. 全球等离子市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东

8. 全球等离子市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第九章 公司简介

  • CSL Behring
  • Grifols
  • Baxter International, Inc.
  • Octapharma
  • Shire（现为武田药品工业株式会社的子公司）
  • Kedrion Biopharma
  • China Biologic Products Holdings, Inc
  • LFB Group, BIoTest AG.

第十章 附录

  • 相关调查
简介目录
Product Code: 32646

Blood Plasma Market Size And Forecast

Blood Plasma Market size was valued at USD 41.26 Billion in 2024 and is projected to reach USD 83.44 Billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032.

  • Blood plasma is the yellowish, liquid component of blood that remains after the blood cells (red cells, white cells, and platelets) have been removed. Comprising about 55% of total blood volume, plasma is primarily composed of water (around 90%), along with proteins, electrolytes, hormones, nutrients, and waste products.
  • It serves as a crucial medium for transporting these substances throughout the body, playing an essential role in maintaining blood pressure, pH balance, and overall homeostasis.
  • Plasma has numerous medical applications, particularly in transfusion medicine and therapeutic treatments. It is vital for the production of clotting factor concentrates for patients with hemophilia and is also used in the formulation of immunoglobulins to treat various immune deficiencies.
  • Additionally, plasma-derived products, such as albumin and clotting factors, are critical in managing conditions like liver disease, shock, and burns. In recent years, plasma has also gained attention for its potential in regenerative medicine, including applications in wound healing and aesthetic treatments.

Global Blood Plasma Market Dynamics

The key market dynamics that are shaping the global blood plasma market include:

Key Market Drivers

  • Rising Demand for Plasma-Derived Therapies: The rising demand for plasma-derived therapies is significantly driving the blood plasma market. Conditions such as hemophilia and immune deficiencies require these therapies for effective treatment. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
  • Growing Awareness of Blood Donation: Growing awareness of the importance of blood donation is increasing the availability of plasma. Public health campaigns are encouraging more individuals to donate, thereby expanding the plasma supply. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
  • Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases, such as autoimmune disorders, is boosting the need for plasma products. This trend emphasizes the essential role of plasma in managing complex health conditions. According to the Centers for Disease Control and Prevention (CDC), as of 2023, an estimated 6% of the U.S. population was living with an autoimmune disease, up from 4.5% in 2018.
  • Rising Investment in Biotechnology: Rising investment in biotechnology and research is enhancing the development of plasma-derived products. Innovations in processing and formulation are leading to more effective therapies and expanded applications. The National Institutes of Health (NIH) reported that funding for research related to plasma-derived therapies reached USD 1.2 Billion in fiscal year 2023, a 15% increase from the previous year.
  • Growing Regulatory Support for Plasma Products: Growing regulatory support for the safety and efficacy of plasma products is fostering market confidence. This supportive environment encourages manufacturers to invest in quality improvements and new product development. The FDA reported a 30% increase in the number of approved plasma-derived therapies in 2023 compared to 2020, reflecting a more streamlined approval process and growing confidence in these products.

Key Challenges:

  • Increasing Regulatory Scrutiny: The increasing regulatory scrutiny surrounding blood plasma collection and use can hinder market expansion. Compliance with stringent guidelines adds complexity and costs for manufacturers and distributors.
  • Rising Concerns over Donor Safety: Rising concerns about donor safety and the potential for adverse effects can affect plasma supply. These apprehensions may discourage individuals from donating, leading to shortages in plasma availability.
  • Growing Public Perception Issues: Growing public perception issues related to blood donation and plasma products can create barriers to market growth. Misinformation or negative sentiments can deter potential donors and consumers alike.
  • Growing Competition from Alternatives: Growing competition from alternative therapies and treatments poses a challenge to the blood plasma market. Emerging technologies may offer substitutes that reduce reliance on traditional plasma-derived therapies.

Key Trends

  • Rising Focus on Immunoglobulin Therapies: The rising focus on immunoglobulin therapies is transforming the blood plasma market. As awareness grows about the effectiveness of these treatments for immune deficiencies and autoimmune diseases, demand is surging. Healthcare providers are increasingly prescribing immunoglobulin therapies, leading to greater investment in plasma collection and processing. This trend highlights the critical role of plasma-derived products in modern medicine.
  • Growing Demand for Plasma-Derived Biologics: There is a growing demand for plasma-derived biologics, including clotting factors and albumin, essential for managing various medical conditions. This trend is fueled by an increasing prevalence of chronic diseases, surgical procedures, and trauma care needs. As more patients require these life-saving therapies, manufacturers are expanding their product lines to meet this demand. The emphasis on high-quality biologics is driving innovation in plasma processing technologies.
  • Increasing Adoption of Automated Plasma Collection: The increasing adoption of automated plasma collection technologies is revolutionizing the industry. Automation improves the efficiency and safety of the collection process, resulting in higher yields and enhanced donor experience. As facilities implement these advanced systems, they can better meet the rising demand for plasma products. This trend not only streamlines operations but also helps attract more donors by minimizing discomfort during the collection process.

Global Blood Plasma Market Regional Analysis

Here is a more detailed regional analysis of the global blood plasma market:

North America

  • North America leads the global blood plasma market, driven by advanced healthcare infrastructure, high awareness of plasma-derived therapies, and a well-established plasma collection network. The United States dominates the region's market share, with its robust regulatory framework and high plasma donation rates.
  • According to the U.S. Food and Drug Administration, there were 943 licensed plasma collection centers in the country as of 2023, demonstrating the significant capacity for plasma collection and processing in the region.
  • The region's dominance is further strengthened by the presence of major plasma fractionation companies and their ongoing investments in expanding production capabilities. Key players like CSL Limited and Grifols S.A. have been actively increasing their plasma collection and fractionation capacities to meet growing demand. In a recent development, Grifols announced in March 2024 the opening of a new plasma fractionation facility in North Carolina, USA, with an annual capacity of processing 6 million liters of plasma, potentially boosting the region's market position.

Asia Pacific

  • The Asia Pacific region is experiencing rapid growth in the Blood Plasma Market, driven by improving healthcare infrastructure, increasing awareness of plasma-derived therapies, and rising prevalence of chronic diseases. Countries like China, India, and Japan are at the forefront of this expansion, with their governments investing heavily in healthcare systems and promoting plasma donation.
  • According to China's National Medical Products Administration, the country's plasma-derived medicinal products market reached 30.8 billion yuan in 2023, highlighting the significant growth potential in the region.
  • The market's growth is further propelled by the rising demand for immunoglobulins and other plasma-derived products for treating various immune deficiencies and rare diseases. Key players in the global blood plasma market are recognizing this potential and expanding their presence in Asia Pacific. In a recent development, Takeda Pharmaceutical Company Limited announced in February 2024 the completion of its new plasma fractionation facility in Guangzhou, China, with an annual production capacity of 1.2 million liters of plasma, aimed at meeting the growing demand for plasma-derived therapies in the region.

Global Blood Plasma Market: Segmentation Analysis

The Global Blood Plasma Market is segmented based on Component, End-User, And Geography.

Blood Plasma Market, By Component

  • Immunoglobulin
  • Albumin
  • Coagulation Factor Concentrates
  • Others

Based on Component, the Global Blood Plasma Market is bifurcated into Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Others. In the blood plasma market, immunoglobulin is the dominant component, primarily due to its critical role in treating various immune deficiencies and autoimmune disorders. Conversely, the albumin segment is rapidly growing, driven by its increasing applications in critical care settings, including surgeries and liver diseases, as well as its use in drug formulation. The rising demand for albumin-based therapies and its versatility in various medical applications are key factors contributing to this segment's expansion.

Blood Plasma Market, By End-User

  • Hospitals
  • Clinics
  • Research Laboratories

Based on End-User, the Global Blood Plasma Market is bifurcated into Hospitals, Clinics, and Research Laboratories. In the blood plasma market, hospitals currently dominate as the primary end-user, driven by the high demand for plasma-derived therapies and transfusions in critical care settings. Meanwhile, the research laboratories segment is experiencing rapid growth, fueled by increasing investments in research related to plasma-derived products and their applications in various medical fields. The expansion of biopharmaceutical research and the development of new therapies utilizing plasma components are key factors contributing to the growth of this segment.

Blood Plasma Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Blood Plasma Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the blood plasma market, North America is the dominant region, primarily due to its advanced healthcare infrastructure, high prevalence of plasma-derived therapies, and significant investment in research and development. Conversely, the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditures, rising awareness of plasma therapies, and the expansion of healthcare facilities in countries like China and India. This growth is further supported by a rising incidence of chronic diseases and the demand for innovative treatment options, positioning Asia Pacific as a key area for future market expansion.

Key Players

The "Global Blood Plasma Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, Grifols, Baxter International, Inc., Octapharma, Shire (now part of Takeda Pharmaceutical Company), Kedrion Biopharma, Bio Products Laboratory, China Biologic Products Holdings, Inc., LFB Group, Biotest AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Plasma Market Key Developments

  • In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments.
  • In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD PLASMA MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BLOOD PLASMA MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BLOOD PLASMA MARKET, BY Component

  • 5.1 Overview
  • 5.2 Immunoglobulin
  • 5.3 Albumin
  • 5.4 Coagulation Factor Concentrates
  • 5.5 Others

6 GLOBAL BLOOD PLASMA MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Research Laboratories

7 GLOBAL BLOOD PLASMA MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East

8 GLOBAL BLOOD PLASMA MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 CSL Behring
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Grifols
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Baxter International, Inc.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Octapharma
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Shire (now part of Takeda Pharmaceutical Company)
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Kedrion Biopharma
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 China Biologic Products Holdings, Inc
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.9 LFB Group, Biotest AG.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 Appendix

  • 11.1 Related Research